A citation-based method for searching scientific literature

Roger Kalla, Julian Teufel, Katharina Feil, Caroline Muth, Michael Strupp. J Neurol 2016
Times Cited: 13







List of co-cited articles
63 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.
M Strupp, R Kalla, J Claassen, C Adrion, U Mansmann, T Klopstock, T Freilinger, H Neugebauer, R Spiegel, M Dichgans,[...]. Neurology 2011
112
53

A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus--effects on slowphase eye velocity, postural stability, locomotion and symptoms.
Jens Claassen, Rainer Spiegel, Roger Kalla, Mary Faldon, Christopher Kennard, Chotipat Danchaivijitr, Stanislaw Bardins, Nicole Rettinger, Erich Schneider, Thomas Brandt,[...]. J Neurol Neurosurg Psychiatry 2013
51
38

Aminopyridines for the treatment of neurologic disorders.
Michael Strupp, Julian Teufel, Andreas Zwergal, Roman Schniepp, Kamran Khodakhah, Katharina Feil. Neurol Clin Pract 2017
30
38

The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
Karina Alviña, Kamran Khodakhah. J Neurosci 2010
113
30

Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus.
Michael Strupp, Matthew J Thurtell, Aasef G Shaikh, Thomas Brandt, David S Zee, R John Leigh. J Neurol 2011
63
23

Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Theresa A Zesiewicz, George Wilmot, Sheng-Han Kuo, Susan Perlman, Patricia E Greenstein, Sarah H Ying, Tetsuo Ashizawa, S H Subramony, Jeremy D Schmahmann, K P Figueroa,[...]. Neurology 2018
43
23

Mutation Spectrum in the CACNA1A Gene in 49 Patients with Episodic Ataxia.
Cèlia Sintas, Oriel Carreño, Noèlia Fernàndez-Castillo, Roser Corominas, Marta Vila-Pueyo, Claudio Toma, Ester Cuenca-León, Isabel Barroeta, Carles Roig, Víctor Volpini,[...]. Sci Rep 2017
19
23

Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
M Strupp, O Schüler, S Krafczyk, K Jahn, F Schautzer, U Büttner, T Brandt. Neurology 2003
156
23

Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.
R A Ophoff, G M Terwindt, M N Vergouwe, R van Eijk, P J Oefner, S M Hoffman, J E Lamerdin, H W Mohrenweiser, D E Bulman, M Ferrari,[...]. Cell 1996
23

Hereditary episodic ataxias.
Joanna C Jen. Ann N Y Acad Sci 2008
30
23

Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Lindsay Horton, Amy Conger, Darrel Conger, Gina Remington, Teresa Frohman, Elliot Frohman, Benjamin Greenberg. Neurology 2013
30
23

Dalfampridine in patients with downbeat nystagmus--an observational study.
Jens Claassen, Katharina Feil, Stanislav Bardins, Julian Teufel, Rainer Spiegel, Roger Kalla, Erich Schneider, Klaus Jahn, Roman Schniepp, Michael Strupp. J Neurol 2013
19
23

4-aminopyridine and cerebellar gait: a retrospective case series.
Roman Schniepp, Max Wuehr, Maximilian Neuhaeusser, Ann Kathrin Benecke, Christine Adrion, Thomas Brandt, Michael Strupp, Klaus Jahn. J Neurol 2012
41
23

Consensus paper: management of degenerative cerebellar disorders.
W Ilg, A J Bastian, S Boesch, R G Burciu, P Celnik, J Claaßen, K Feil, R Kalla, I Miyai, W Nachbauer,[...]. Cerebellum 2014
88
23

Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.
M Strupp, R Kalla, M Dichgans, T Freilinger, S Glasauer, T Brandt. Neurology 2004
145
23

Treatment of nystagmus.
Matthew J Thurtell, R John Leigh. Curr Treat Options Neurol 2012
18
15

Pearls & Oy-sters: Episodic ataxia type 2: Case report and review of the literature.
Elan L Guterman, Brian Yurgionas, Alexandra B Nelson. Neurology 2016
12
16

New insights into the pathogenesis and therapeutics of episodic ataxia type 1.
Maria Cristina D'Adamo, Sonia Hasan, Luca Guglielmi, Ilenio Servettini, Marta Cenciarini, Luigi Catacuzzeno, Fabio Franciolini. Front Cell Neurosci 2015
40
15

Eye movement disorders are an early manifestation of CACNA1A mutations in children.
Esther M Tantsis, Deepak Gill, Lyn Griffiths, Sachin Gupta, John Lawson, Neven Maksemous, Robert Ouvrier, Florence Riant, Robert Smith, Christopher Troedson,[...]. Dev Med Child Neurol 2016
38
15

Clinical spectrum of episodic ataxia type 2.
J Jen, G W Kim, R W Baloh. Neurology 2004
179
15

Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation.
Tracey D Graves, Yoon-Hee Cha, Angelika F Hahn, Richard Barohn, Mohammed K Salajegheh, Robert C Griggs, Brian N Bundy, Joanna C Jen, Robert W Baloh, Michael G Hanna. Brain 2014
55
15

The clinical and genetic heterogeneity of paroxysmal dyskinesias.
Alice R Gardiner, Fatima Jaffer, Russell C Dale, Robyn Labrum, Roberto Erro, Esther Meyer, Georgia Xiromerisiou, Maria Stamelou, Matthew Walker, Dimitri Kullmann,[...]. Brain 2015
78
15


Primary episodic ataxias: diagnosis, pathogenesis and treatment.
J C Jen, T D Graves, E J Hess, M G Hanna, R C Griggs, R W Baloh. Brain 2007
200
15

Clinical, genetic, neurophysiological and functional study of new mutations in episodic ataxia type 1.
Susan Elizabeth Tomlinson, Sanjeev Rajakulendran, Stella Veronica Tan, Tracey Dawn Graves, Doris-Eva Bamiou, Robyn W Labrum, David Burke, Carolyn M Sue, Paola Giunti, Stephanie Schorge,[...]. J Neurol Neurosurg Psychiatry 2013
31
15

Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot trial.
Katharina Feil, Jens Claaßen, Stanislavs Bardins, Julian Teufel, Siegbert Krafczyk, Erich Schneider, Roman Schniepp, Klaus Jahn, Roger Kalla, Michael Strupp. Neurology 2013
25
15

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Andrew D Goodman, Theodore R Brown, Keith R Edwards, Lauren B Krupp, Randall T Schapiro, Ron Cohen, Lawrence N Marinucci, Andrew R Blight. Ann Neurol 2010
231
15

4-Aminopyridine in multiple sclerosis: prolonged administration.
D Stefoski, F A Davis, W E Fitzsimmons, S S Luskin, J Rush, G W Parkhurst. Neurology 1991
87
15

4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis.
Jodie M Burton, Chaim M Bell, Scott E Walker, Paul W O'Connor. Neurology 2008
33
15

Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion.
Jennifer F Iaci, Tom J Parry, Zhihong Huang, Seth P Finklestein, Jingmei Ren, Dana K Barrile, Matthew D Davenport, Rui Wu, Andrew R Blight, Anthony O Caggiano. Stroke 2013
11
18

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Andrew D Goodman, Theodore R Brown, Lauren B Krupp, Randall T Schapiro, Steven R Schwid, Ron Cohen, Lawrence N Marinucci, Andrew R Blight. Lancet 2009
357
15

Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
Richard Macdonell, Guy Nagels, David-Axel Laplaud, Carlo Pozzilli, Brigit de Jong, Ana Martins da Silva, Richard Nicholas, Jeannette Lechner-Scott, Julia A Gaebler, Sonalee Agarwal,[...]. Mult Scler 2016
19
15


4-Aminopyridine improves clinical signs in multiple sclerosis.
D Stefoski, F A Davis, M Faut, C L Schauf. Ann Neurol 1987
142
15

4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety.
H A Van Diemen, C H Polman, J C Koetsier, A C Van Loenen, J J Nauta, F W Bertelsmann. Clin Neuropharmacol 1993
72
15

4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
C H Polman, F W Bertelsmann, R de Waal, H A van Diemen, B M Uitdehaag, A C van Loenen, J C Koetsier. Arch Neurol 1994
44
15

The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.
Sarah A Morrow, Heather Rosehart, Andrew M Johnson. Mult Scler Relat Disord 2017
23
15

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.
C T Bever, D Young, P A Anderson, A Krumholz, K Conway, J Leslie, N Eddington, K I Plaisance, H S Panitch, S Dhib-Jalbut. Neurology 1994
141
15


Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system.
Verena-Isabell Leussink, Mark Stettner, Clemens Warnke, Hans-Peter Hartung. J Peripher Nerv Syst 2016
8
25

Downbeat nystagmus: aetiology and comorbidity in 117 patients.
J N Wagner, M Glaser, T Brandt, M Strupp. J Neurol Neurosurg Psychiatry 2008
97
15

Dalfampridine in chronic sensorimotor deficits after ischemic stroke: A proof of concept study.
David M Simpson, James Goldenberg, Scott Kasner, Marshall Nash, Michael J Reding, Richard M Zweifler, Gustavo Suarez, Ping Zhao, Herbert R Henney, Adrian L Rabinowicz,[...]. J Rehabil Med 2015
10
20

4-Aminopyridine promotes functional recovery and remyelination in acute peripheral nerve injury.
Kuang-Ching Tseng, Haiyan Li, Andrew Clark, Leigh Sundem, Michael Zuscik, Mark Noble, John Elfar. EMBO Mol Med 2016
33
15

Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
Linard Filli, Björn Zörner, Sandra Kapitza, Katja Reuter, Lilla Lörincz, David Weller, Tabea Sutter, Tim Killeen, Philipp Gruber, Jens A Petersen,[...]. Neurology 2017
26
15

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
A D Goodman, J A Cohen, A Cross, T Vollmer, M Rizzo, R Cohen, L Marinucci, A R Blight. Mult Scler 2007
109
15

Effects of 4-aminopyridine in patients with multiple sclerosis.
R E Jones, J R Heron, D H Foster, R S Snelgar, R J Mason. J Neurol Sci 1983
120
15

Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine.
P M Rossini, P Pasqualetti, C Pozzilli, M G Grasso, E Millefiorini, A Graceffa, G A Carlesimo, G Zibellini, C Caltagirone. Mult Scler 2001
92
15

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.
S R Schwid, M D Petrie, M P McDermott, D S Tierney, D H Mason, A D Goodman. Neurology 1997
143
15

The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
H A van Diemen, C H Polman, T M van Dongen, A C van Loenen, J J Nauta, M J Taphoorn, H K van Walbeek, J C Koetsier. Ann Neurol 1992
129
15

Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
Sarah D Broicher, Linard Filli, Olivia Geisseler, Nicole Germann, Björn Zörner, P Brugger, M Linnebank. J Neurol 2018
20
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.